Suresnes (France), Feb. 27, 2025 – Servier announces the appointment of Nitza Thomasson as Executive Director R&D Neurology effective March 1, 2025.
In her new role, Nitza Thomasson will be responsible for the Group’s R&D strategy in the field of neurology, leading and accelerating the research and development of new treatments for patients with rare neurological diseases. She will play a key role in strengthening the R&D pipeline and will work closely with the R&D teams, as well as with all the Group’s other business lines and external strategic partners. As part of its 2030 strategy, the Servier Group will dedicate significant resources and investments to build a robust and promising R&D pipeline in the field of neurology. Through new treatments, the aim is to meet the most important medical needs of these often devastating neurological diseases.
Nitza Thomasson has recognized international expertise in neuroscience with a multidisciplinary background in R&D within the pharmaceutical industry and at biotechnology companies. She holds a master’s degree (École Polytechnique, ENS) and a PhD in Neuroscience (Paris Sorbonne). She then conducted postdoctoral research at Northwestern University (Chicago, Illinois, USA) and Hôpital Sainte-Anne (Paris). As an entrepreneur driven by innovation, Nitza co-founded BrainEver and GenSight Biologics. She has also held executive positions at Sanofi, Fovea, and Tissium. Finally, she founded NTZConsulting, supporting a large number of companies in their pharmaceutical development strategies for more than seven years. Her return to Servier marks a new stage, after serving as Head of Biological Studies and Head of Clinical Studies in neurology from November 2001 to April 2009. With a solid background in leadership, research management and the development of innovative therapies, she brings a strategic and scientific vision to accelerate the Group’s expansion in neurology.
Media contact
Marion Breyer: presse@servier.com I Tel. +33 (0)1 55 72 40 21
About Servier
Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.
As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.
Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.
To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe and in Brazil.
In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.
Headquartered in France, Servier relies on a strong geographical footprint in close to 150 countries and achieved a revenue of €5.9 billion in 2023.